Skip to main content
. 2018 Nov 8;11(4):121. doi: 10.3390/ph11040121
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
T2DM type 2 diabetes mellitus
HbA1c glycosylated haemoglobin
PPAR-γ peroxisome proliferator-activated receptor-γ
RCT randomized controlled trial
FPG fasting plasma glucose
FFA free fatty acids
IR insulin resistance
HCC hepatocellular carcinoma
CVD cardiovascular disease
ROS reactive oxygen species
TZD Thiazolidinediones
GLP-1 Glucagon-like pepide-1
SGLT-2 Sodium-glucose cotransporter 2
DPP-4 Dipeptidyl peptidase-4